Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003)

CONCLUSIONS: DAC HYP demonstrated superior efficacy compared with IFNβ-1a across key clinical, radiographic, and patient-reported MS outcome measures in relapsing MS patients. Risks were manageable with appropriate monitoring. Study Supported by: Biogen Idec and AbbVie Biotherapeutics.Disclosure: Dr. Kappos has received personal compensation for activities with Actelion Pharmaceuticals. Dr. Selmaj has received personal compensation for activities with Genzyme Corporation, Novartis, Ono Pharmaceutical, Roche Diagnostics Corporation, Synthon, Teva Neuroscience, and Biogen Idec. as a consultant and/or speaker. Dr. Arnold has received personal compensation for activities with Acorda, Bayer Healthcare, Biogen Idec, Merck Serono, Genentech, Genzyme, GlaxoSmithKline, Medimmune, Novartis, Receptos, Inc., Roche, Sanofi-Aventis, and Teva. Dr. Havrdovahas received personal compensation for activities with Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis Pharmaceuticals Inc., Genzyme Corp., and Teva Neuroscience. Dr. Boyko has received personal compensation for activities with Bayer Schering, Merck Serono, Teva, Novartis, Biogen Idec, Nycomed, Genzyme, and Sanofi-Aventis as a consultant and/or speaker. Dr. Kaufman has received personal compensation for activities with Biogen Idec, Acorda Therapeutics, Genzyme, Novartis, and Teva. Dr. Weindl has received personal compensation for activities with Bayer HealthCare, Biogen Idec, Fresenius Medical Care, GlaxoSmithKline, GW Pharmaceu...

Source: Neurology - April 8, 2015 Category: Neurology Authors: Kappos, L., Selmaj, K., Arnold, D., Havrdova, E., Boyko, A., Kaufman, M., Wiendl, H., Rose, J., Greenberg, S., Sweetser, M., Riester, K., Elkins, J. Tags: Clinical Trial Outcomes in Multiple Sclerosis Source Type: research